Samuel Ross, MD
Emergency Medicine · Wakeman, OHNPI 1275979296
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,268 and has fallen 98.0% since, to $25 in 2025. Among emergency medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$727
- Novo Nordisk$540
- Pfizer$326
- AstraZeneca$258
- Lilly USA, LLC$209
- Takeda Pharmaceuticals U.S.A., Inc.$156
- plus $942 from 21 others
Across 7 payments — averaging $16,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$114K
- Indivior Inc.$150
What the payments were for
- Food & beverage$3,12799%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $727 |
| Novo Nordisk | 34 | $540 |
| Pfizer | 23 | $326 |
| AstraZeneca | 19 | $258 |
| Lilly USA, LLC | 15 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $148 |
| Boehringer Ingelheim | 9 | $136 |
| GSK | 9 | $122 |
| Biohaven Pharmaceuticals, Inc. | 4 | $72 |
| Novartis | 4 | $63 |
| Grifols USA, LLC | 3 | $54 |
| Electromed, Inc. | 4 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Eisai Inc. | 3 | $41 |
| Sanofi | 2 | $33 |
| Bayer | 2 | $31 |
| Johnson & Johnson | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Amgen | 1 | $14 |
| Indivior Inc. | 1 | $13 |
| Alkermes, Inc. | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $11 |
How this compares
$3,159 in reported general payments places this provider in the 95th percentile of 2,431 emergency medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $85,071 |
| TrulicityDulaglutide | 39 | $67,381 |
| EliquisApixaban | 60 | $59,626 |
| JardianceEmpagliflozin | 33 | $36,859 |
| XareltoRivaroxaban | 21 | $17,608 |
| FarxigaDapagliflozin Propanediol | 13 | $16,590 |
| JanuviaSitagliptin Phosphate | 17 | $15,866 |
| MounjaroTirzepatide | 20 | $14,859 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $7,259 |
| Humalog Kwikpen U-100Insulin Lispro | 29 | $6,907 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 15 | $6,859 |
| Omeprazole | 181 | $2,754 |
| MyrbetriqMirabegron | 13 | $2,690 |
| Atorvastatin Calcium | 302 | $2,509 |
| Potassium Chloride | 110 | $2,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $540 | $85,07163 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $209 | $82,24059 claims |
| PfizerEliquis | $326 | $59,62660 claims |
| Boehringer IngelheimJardiance | $136 | $36,85933 claims |
| Johnson & JohnsonXarelto | $30 | $17,60821 claims |
| AstraZenecaFarxiga | $258 | $16,59013 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $2,69013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,431 emergency medicine providers in Ohio.
Other emergency medicine in Wakeman
- James NeuenschwanderMount Vernon$939K
- Thomas NaumoffBeachwood$746K
- Paul HogyaSouth Lebanon$468K
- Gregory FermannCincinnati$210K
- Anne StubbsColumbus$190K
- Natalie KreitzerCincinnati$150K
- Michael LyonsColumbus$140K
- Kiran FaryarWest Chester$125K
- Jordan BonomoCincinnati$92K
- Lori StolzCincinnati$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.